Sinco Pharmaceuticals Holdings Limited (HKG:6833)
Hong Kong · Delayed Price · Currency is HKD 0.1400
-0.0050 (-3.45%)
Sep 11, 2026, 3:57 PM HKT
HKG:6833 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1,921 | 2,085 | 2,821 | 2,540 | 2,272 | 2,024 | |
Revenue Growth | -22.85% | -26.11% | 11.07% | 11.82% | 12.22% | -1.26% |
Cost of Revenue | 1,706 | 1,862 | 2,521 | 2,217 | 1,966 | 1,659 |
Gross Profit | 215.48 | 222.09 | 299.94 | 323.28 | 305.87 | 364.95 |
Selling, General & Admin | 151.37 | 140.32 | 189.92 | 202.58 | 198.44 | 171.38 |
Operating Expenses | 151.89 | 147.42 | 186 | 206.82 | 204.64 | 172.4 |
Operating Income | 63.59 | 74.68 | 113.95 | 116.46 | 101.22 | 192.55 |
Interest Expense | -13.06 | -15.37 | -12.55 | -9.81 | -13.81 | -21.45 |
Interest & Investment Income | 3.82 | 4.02 | 6.12 | 5.97 | 2.42 | 1.31 |
Currency Exchange Gain (Loss) | -13.85 | -11.15 | -12.6 | -8.64 | 15.98 | -3.55 |
Other Non Operating Income (Expenses) | 3.15 | -3.92 | 8.93 | -1.13 | -3.89 | -1.49 |
EBT Excluding Unusual Items | 43.65 | 48.26 | 103.84 | 102.85 | 101.93 | 167.39 |
Gain (Loss) on Sale of Assets | -1.81 | - | - | 0.04 | - | - |
Other Unusual Items | - | - | -4.92 | -3 | -2.63 | - |
Pretax Income | 41.84 | 48.26 | 98.92 | 99.88 | 99.29 | 167.39 |
Income Tax Expense | 11.47 | 13.41 | 56.88 | 57.53 | 29.83 | 32.3 |
Earnings From Continuing Operations | 30.37 | 34.85 | 42.05 | 42.35 | 69.46 | 135.08 |
Net Income | 30.37 | 34.85 | 42.05 | 42.35 | 69.46 | 135.08 |
Net Income to Common | 30.37 | 34.85 | 42.05 | 42.35 | 69.46 | 135.08 |
Net Income Growth | -28.64% | -17.11% | -0.73% | -39.03% | -48.58% | 14.34% |
Shares Outstanding (Basic) | 2,033 | 2,033 | 2,033 | 2,033 | 2,032 | 1,737 |
Shares Outstanding (Diluted) | 2,033 | 2,033 | 2,033 | 2,033 | 2,032 | 1,737 |
Shares Change | - | - | - | 0.07% | 16.93% | 2.69% |
EPS (Basic) | 0.01 | 0.02 | 0.02 | 0.02 | 0.03 | 0.08 |
EPS (Diluted) | 0.01 | 0.02 | 0.02 | 0.02 | 0.03 | 0.08 |
EPS Growth | -26.95% | -15.00% | 0% | -41.18% | -56.28% | 11.39% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 331.62 | 197.55 | -268.04 | 324.15 | 22.39 | 282.19 |
Free Cash Flow Per Share | 0.16 | 0.10 | -0.13 | 0.16 | 0.01 | 0.16 |
Dividend Per Share | - | 0.002 | 0.002 | 0.004 | 0.009 | - |
Dividend Growth | - | -20.12% | -46.92% | -59.16% | - | - |
Gross Margin | 11.22% | 10.65% | 10.63% | 12.73% | 13.46% | 18.03% |
Operating Margin | 3.31% | 3.58% | 4.04% | 4.58% | 4.46% | 9.51% |
Profit Margin | 1.58% | 1.67% | 1.49% | 1.67% | 3.06% | 6.67% |
Free Cash Flow Margin | 17.26% | 9.48% | -9.50% | 12.76% | 0.99% | 13.94% |
EBITDA | 83.92 | 93.45 | 132.52 | 127.34 | 109.01 | 197.69 |
EBITDA Margin | 4.37% | 4.48% | 4.70% | 5.01% | 4.80% | 9.77% |
D&A For EBITDA | 20.32 | 18.78 | 18.58 | 10.88 | 7.79 | 5.14 |
EBIT | 63.59 | 74.68 | 113.95 | 116.46 | 101.22 | 192.55 |
EBIT Margin | 3.31% | 3.58% | 4.04% | 4.58% | 4.46% | 9.51% |
Effective Tax Rate | 27.42% | 27.78% | 57.50% | 57.60% | 30.04% | 19.30% |